Update on abatacept: A selective costimulation modulator for rheumatoid arthritis

Annals of Pharmacotherapy

Volumn 41, Issue 7-8, 2007, Pages 1153-1162

  Bruce, Susan P ^a   Boyce, Eric G ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Abatacept; CCTLA4 Ig; Costimulation modulator; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; BELATACEPT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD SALT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANAPHYLAXIS; BRONCHITIS; CLINICAL TRIAL; COCHRANE LIBRARY; CONNECTIVE TISSUE DISEASE; COUGHING; DATA ANALYSIS; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG USE; DYSPEPSIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; INFECTION; INFLUENZA; INJECTION SITE REACTION; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PHARYNGITIS; PRIORITY JOURNAL; RASH; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SCISEARCH; SCORING SYSTEM; SINUSITIS; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANIMALS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNOCONJUGATES;

EID: 34547197857     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K057     Document Type: Review

References (40)

1. Doan T, Massarotti E. Rheumatoid arthritis: an overview of new and emerging therapies. J Clin Pharmacol 2005;45:751-62.
2. Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. Am J Health Syst Pharm 2006;63:2451-65.
3. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 2004;63:627-33.
4. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
5. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
6. Mariette X. Emerging biological therapies in rheumatoid arthritis. Joint Bone Spine 2004;71:470-4.
7. Panayi GS, Corrigall VM, Pitzalis C. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am 2001;27:317-34.
8. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
9. Budd RC, Former KA. T Lymphocytes. In: Harris ED, Budd RC, Firestein GS, et al. eds. Kelley's textbook of rheumatology. 7th ed. Philadelphia: Elsevier/Saunders, 2005:133-52.
10. Kremer JM. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J Clin Rheumatol 2005;11(suppl): S55-62.
11. Kremer JM. Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis. Rheum Dis Clin North Am 2004;30:381-91.
12. Package insert. Orencia (abatacept) Princeton, NJ: Bristol-Myers Squibb Co., December 2005.
13. Davis P, Nadler S, Suchard S. Abatacept differentially modulates B-cell and dendritic cell-stimulated T cell effector function (abstract). Ann Rheum Dis 2006;64:400.
14. Emery P, Westhovens R, Leon G, et al. Beneficial effects of the selective co-stimulation modulator abatacept on biomarkers of rheumatoid arthritis immunopathology in patients with an inadequate response to methotrexate or TNF-inhibitor treatment (abstract). Ann Rheum Dis 2005;64:1407.
15. Weisman MH, Durez P, Hallegua D, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006;33:2162-6.
16. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-9.
17. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
18. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
19. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71.
20. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76.
21. Weinblatt ME, Schiff MH, Goldman A, et al. Selective co-stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trial. Ann Rheum Dis 2007;66:228-34. Epub 2006 Aug 25. DOI 10.1136/ard2006.055111
22. Kremer J, Shergy W, Tindall E, et al. Sustained clinical efficacy demonstrated by the selective co-stimulation modulator abatacept (CTLA4Ig) in combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate (abstract). Arthritis Rheum 2004;50:S182.
23. Kremer J, Emery P, Becker JP, et al. Abatacept provides significant and sustained benefits in clinical and patient-reported outcomes through 2 yrs in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX): the long-term extension (LTE) of the AIM trial (abstract). Ann Rheum Dis 2006;65:S327.
24. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
25. Emery P, Kosinski M, Li T, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol 2006;33:681-9.
26. Dougados M, Westhovens R, St Clair EW, et al. Sustained remission and major clinical response at 2 years shown with abatacept (CTLA4Ig) in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate (abstract). Arthritis Rheum 2004; 50:S185.
27. Westhovens R, Emery P, Aranda R, Becker JP, Zhou Y, Dougados M. Abatacept provides sustained clinical benefit through 3 years in rheumatoid arthritis (RA) patients with inadequate responses to methotrexate (MTX) (abstract). Ann Rheum Dis 2006;65:S512.
28. Sibilia J, Schiff M, Genovese MC, et al. Sustained improvements in disease activity score 28 (DAS28) and patient (PT)-reported outcomes (PRO) with abatacept (ABA) in rheumatoid arthritis (RA) pts. with an inadequate response to anti-TNF therapy: the long-term extension (LTE) of the ATTAIN trial (abstract). Ann Rheum Dis 2006;65:S501.
29. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807-16.
30. Ruperto N, Lovell DJ, Prieur A, et al. Efficacy and safety of abatacept in children and adolescents with active juvenile arthritis (JIA) (abstract). Ann Rheum Dis 2006;65:248.
31. Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192:681-94.
32. Abatacept in the treatment and prevention of active systemic lupus erythematosus (SLE) flares in combination with prednisone. National Library of Medicine. http://clinicaltrials.gov/ct/show/NCT00119678 (accessed 2007 Mar 13).
33. Moreland LW, Combe B, Steinfeld S, et al. An integrated safety analysis of abatacept in the treatment of rheumatoid arthritis (RA) across patient types and background therapies (abstract). Ann Rheum Dis 2006;65:S110.
34. Amezcua-Guerra LM, Hernandez-Martinez B, Pineda C, Bojalil R. Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis. Gut 2006;55:1059-60.
35. Haggerty HG, Abbott MA, Reilly TP, et al. Abatacept displays low levels of immunogenicity in the treatment of rheumatoid arthritis (abstract). Ann Rheum Dis 2006;65:S319.
36. Rychly DJ, Dipiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005;25:1181-92.
37. Haggerty H, Bigbee C, Gonchoroff D, Flynn J. Abatacept treatment does not impair host resistance to chronic Mycobacterium tuberculosis infection in mice (abstract). Ann Rheum Dis 2006;65:319a.
38. Simon TA, Smitten AL, Boodhoo T, et al. Observed and expected malignancies in the abatacept clinical development program: an epidemiological assessment (abstract). Ann Rheum Dis 2006;65:S489.
39. Corbo M, Tay L, Leon F, Vratsanos G. A single dose of abatacept does not prevent the development of a positive immune response to tetanus and pneumococcal vaccines (abstract). Ann Rheum Dis 2006;65:184.
40. Davies A, Cifaldi MA, Weisman M, Segurado OG. Cost effectiveness of the 3 TNF antagonists vs abatacept in the treatment of moderate to severe rheumatoid arthritis (RA) (abstract). Ann Rheum Dis 2006;65:S278.